The development of the Alluminox platform has only just begun.
Thirteen years after a father's cancer diagnosis set one founder on a mission to reimagine how tumors are destroyed, Rakuten Medical is reshaping its leadership to meet the demands of its most consequential chapter. Mickey Mikitani, who built the company around photoimmunotherapy — a treatment that uses light to selectively unmake cancer cells — is stepping into the role of Executive Chairman, entrusting daily command to Minami Maeda as the company drives toward a 2028 FDA filing. The transition is less a departure than a deepening of focus: the vision remains, but the work of turning science into medicine now requires a different kind of presence at the helm.
- A 2028 FDA Biologics License Application for ASP-1929 creates an unforgiving timeline that demands operational precision above all else.
- The global Phase 3 trial spanning the US, Taiwan, Japan, and Ukraine is enrolling patients ahead of schedule — a rare and fragile advantage the company cannot afford to squander.
- Mikitani's shift to Executive Chairman signals that visionary founding energy and day-to-day execution are no longer the same job at this stage of the company's life.
- Maeda, a nine-year veteran of the organization, steps into the CEO role carrying explicit founder confidence and the weight of patients whose recurrent head and neck cancers have few remaining options.
- Commercial readiness across multiple international markets must now be built in parallel with clinical and regulatory work, compressing the margin for organizational drift.
Mickey Mikitani founded Rakuten Medical after his father's cancer diagnosis led him to photoimmunotherapy — a treatment that pairs an antibody-dye conjugate with targeted red light to selectively destroy tumor cells. That personal origin story now meets a corporate inflection point: Mikitani is stepping back from the CEO role, handing operational leadership to Minami Maeda, who has served as president since 2017, while remaining as Executive Chairman to guide long-term strategy.
The restructuring is timed deliberately. Rakuten Medical is targeting a 2028 submission of a Biologics License Application to the FDA for ASP-1929, its lead candidate already approved in Japan as Akalux for unresectable head and neck cancers. A global Phase 3 trial — testing the drug alongside pembrolizumab as a first-line treatment for recurrent head and neck cancer — is enrolling ahead of schedule across the United States, Taiwan, Japan, and Ukraine.
The science behind the platform is precise: the drug targets epidermal growth factor receptor, a protein found on multiple solid tumor types. Once bound to cancer cells, red light at 690 nanometers triggers a photochemical reaction that ruptures the cell membrane and, preclinical data suggest, activates the body's own immune response against the tumor. Beyond head and neck cancer, the company is exploring the platform's reach across breast, lung, colorectal, and other solid tumors.
Maeda's elevation reflects a recognition that the years ahead demand execution over vision — manufacturing readiness, regulatory navigation, and commercial infrastructure across multiple countries, all running simultaneously. Mikitani has been explicit about his confidence in Maeda's capabilities, and the founder's continued presence as chairman ensures strategic continuity. For patients with recurrent or inoperable head and neck cancer, the quality of that execution is not an abstraction — it is the difference between a promising therapy and an available one.
Mickey Mikitani founded Rakuten Medical thirteen years ago with a personal mission rooted in loss. When his father was diagnosed with cancer, Mikitani encountered photoimmunotherapy—a treatment approach that would become the center of his professional life. Now, as the company stands at a critical inflection point, he is stepping back from the day-to-day role of chief executive, handing the reins to Minami Maeda, who has served as president since joining the organization in 2017.
The transition reflects a deliberate restructuring as Rakuten Medical prepares for what may be the most consequential years in its history. The company is racing toward a 2028 submission of a Biologics License Application to the U.S. Food and Drug Administration for ASP-1929, its lead drug candidate. This photoimmunotherapy treatment combines an antibody-dye conjugate with targeted red light illumination to attack cancer cells. The approach has already won approval in Japan for unresectable head and neck cancers under the brand name Akalux, paired with a laser delivery system called BioBlade. Now the company wants to bring it to American patients, and the window for regulatory success is narrowing.
Maeda's elevation to CEO signals that Rakuten Medical believes it needs a full-time operational leader focused on execution rather than long-term vision. Mikitani will remain as Executive Chairman, continuing to shape strategy and oversee the company's broader mission—what Rakuten Medical calls "Conquering Cancer." But the day-to-day work of accelerating clinical trials, preparing regulatory submissions, and building commercial infrastructure will fall to Maeda. The company is currently running a global Phase 3 trial called ASP-1929-381, which tests the drug in combination with pembrolizumab as a first-line treatment for recurrent head and neck cancer. Patient enrollment is already ahead of schedule across the United States, Taiwan, Japan, and Ukraine.
The stakes are substantial. Photoimmunotherapy works through a mechanism that Rakuten Medical describes as inducing rapid and selective cell death. The drug component targets epidermal growth factor receptor, a protein expressed on multiple solid tumors including breast, lung, colorectal, prostate, and pancreatic cancers. Once the drug binds to cancer cells, red light at 690 nanometers activates it, triggering a photochemical reaction that damages the cancer cell membrane. The company's preclinical data suggest this process also triggers immune activation—the body's own defenses mobilize against the tumor.
Beyond the head and neck indication, Rakuten Medical is expanding the platform's reach. With support from external grants, the company is exploring whether photoimmunotherapy can work across diverse tumor types. This expansion is being supported by the continued adoption of Akalux in Japan, where the treatment has already proven itself in clinical practice. The company is also working with regional strategic partners to secure approvals in additional markets, leveraging both the clinical data package from its trials and real-world evidence from Japanese patients.
Maeda's appointment comes at a moment when biotech companies face intense pressure to deliver on their promises. The clinical trial is moving faster than expected. Regulatory timelines are tightening. Commercial readiness—the ability to manufacture, distribute, and support a new cancer therapy across multiple countries—requires disciplined execution and organizational focus. Mikitani's confidence in Maeda is explicit. In his statement, the founder emphasized that Maeda has demonstrated "strong leadership, strategic insight and execution capabilities" since 2017, and that he looks forward to supporting him in the new role.
For patients with head and neck cancer, particularly those whose tumors have recurred or cannot be surgically removed, this leadership transition carries real weight. The company's ability to navigate the regulatory pathway, complete its trials on schedule, and ultimately bring photoimmunotherapy to market depends on the quality of execution in the years ahead. Rakuten Medical is betting that Maeda, working closely with Mikitani's strategic guidance, can deliver on that promise.
Notable Quotes
The development of the Alluminox platform has only just begun. We must continue to grow as a company so that we can bring this innovation to patients around the world.— Mickey Mikitani, outgoing CEO and incoming Executive Chairman
As we now enter a critical phase, our focus is on delivering against key priorities, including advancing the ASP-1929-381 trial, preparing for regulatory milestones and expanding our commercial footprint.— Minami Maeda, incoming CEO
The Hearth Conversation Another angle on the story
Why does a founder step back from the CEO role at such a critical moment? Isn't that when you'd want your founder's vision driving the ship?
You'd think so, but there's a difference between vision and execution. Mikitani has spent thirteen years building this company around a personal mission. Now it needs someone whose full attention is on hitting regulatory milestones, managing a global trial, and preparing for commercial launch. That's a different skill set.
So Maeda is the operations person and Mikitani is the strategist?
Roughly, yes. But it's not a clean split. Mikitani stays as Executive Chairman—he's still deeply involved. He's just not in the daily meetings about trial enrollment numbers or FDA submission timelines. Maeda owns those.
The trial is enrolling ahead of schedule. Does that make the leadership change easier or harder?
Easier, in a way. It means the science is working, the patient interest is there. But it also means the pressure is on to not stumble at the finish line. You've got momentum—you can't afford to lose it to organizational confusion or slow decision-making.
What happens if the FDA says no in 2028?
That's the unspoken weight here. Photoimmunotherapy has been in development for years. Japan approved it. The Phase 3 data will tell the story. But if the FDA isn't convinced, this company faces a very different future. That's why you need a CEO who can execute flawlessly.
And if it works? If they get approval?
Then Rakuten Medical becomes a commercial oncology company overnight. Manufacturing, distribution, reimbursement, patient access—all of that has to be ready. That's what Maeda is being hired to build.